Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Powell

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
Journal of Translational Medicine|February 14, 2013
IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cellsSaskia J A M Santegoets, Annelies W Turksma, Megan M Suhoski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive TherapyEmese Zsiros, Priyanka Duttagupta, Denarda Dangaj, et al.
Science Translational Medicine|May 18, 2012
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patientsAndrew J Rech, Rosemarie Mick, Sunil Martin, et al.
Cancers|October 16, 2025
A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid TumorsCristina Aparicio, Mónica Queipo, Marina Belver, et al.
Blood Cancer Journal|August 15, 2021
NKG2D-CAR-transduced natural killer cells efficiently target multiple myelomaAlejandra Leivas, Antonio Valeri, Laura Córdoba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2013
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedsideCheryl Lai-Lai Chiang, Lana E Kandalaft, Janos Tanyi, et al.
Nature Communications|July 17, 2021
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targetingAdham S Bear, Tatiana Blanchard, Joseph Cesare, et al.
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
The Journal of Clinical Investigation|September 17, 2024
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsAdham S Bear, Rebecca B Nadler, Mark H O'Hara, et al.
JCO Precision Oncology|September 14, 2020
<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerYing L Liu, Pier Selenica, Qin Zhou, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
Journal of Translational Medicine|February 14, 2013
IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cellsSaskia J A M Santegoets, Annelies W Turksma, Megan M Suhoski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive TherapyEmese Zsiros, Priyanka Duttagupta, Denarda Dangaj, et al.
Science Translational Medicine|May 18, 2012
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patientsAndrew J Rech, Rosemarie Mick, Sunil Martin, et al.
Cancers|October 16, 2025
A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid TumorsCristina Aparicio, Mónica Queipo, Marina Belver, et al.
Blood Cancer Journal|August 15, 2021
NKG2D-CAR-transduced natural killer cells efficiently target multiple myelomaAlejandra Leivas, Antonio Valeri, Laura Córdoba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2013
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedsideCheryl Lai-Lai Chiang, Lana E Kandalaft, Janos Tanyi, et al.
Nature Communications|July 17, 2021
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targetingAdham S Bear, Tatiana Blanchard, Joseph Cesare, et al.
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
The Journal of Clinical Investigation|September 17, 2024
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsAdham S Bear, Rebecca B Nadler, Mark H O'Hara, et al.
JCO Precision Oncology|September 14, 2020
<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerYing L Liu, Pier Selenica, Qin Zhou, et al.
Pageof 14